The Scottish Medicines Consortium (SMC) has announced that the anti-fibrotic medicine nintedanib has been accepted for use by NHS Scotland for the treatment of patients with the lung scarring disease pulmonary fibrosis. Action for Pulmonary Fibrosis (APF) has spearheaded a campaign for patients in Scotland with the support of patients, families and medical experts, to […]
Read More… from Scotland: Hope for patients with pulmonary fibrosis